These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31025722)

  • 1. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.
    Kato M; Hirakawa A; Sato H; Hanazawa R; Naito Y; Tochigi K; Sano T; Ishida S; Funahashi Y; Fujita T; Matsukawa Y; Hattori R; Tsuzuki T
    Int J Clin Oncol; 2021 Apr; 26(4):764-769. PubMed ID: 33385274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens.
    Kimura K; Tsuzuki T; Kato M; Saito AM; Sassa N; Ishida R; Hirabayashi H; Yoshino Y; Hattori R; Gotoh M
    Prostate; 2014 May; 74(6):680-7. PubMed ID: 24481730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].
    Sakamoto N; Ueda S; Mizoguchi H; Kawahara I; Kobayashi T; Hamaguchi M; Yoshikawa M
    Nihon Hinyokika Gakkai Zasshi; 2017; 108(1):5-11. PubMed ID: 29367511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
    Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic parameter for high risk prostate cancer patients at initial presentation.
    Kato M; Kimura K; Hirakawa A; Kobayashi Y; Ishida R; Kamihira O; Majima T; Funahashi Y; Sassa N; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2018 Jan; 78(1):11-16. PubMed ID: 29094384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
    Seyrek N; Hollemans E; Andrinopoulou ER; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Remmers S; Schoots IG; van Leenders GJLH
    Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    Khani F; Epstein JI
    Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of the Intraductal Carcinoma of the Prostate on the Short-Term Oncological Outcomes.
    Kalemci S; Kizilay F; Simsir A; Emre Ergun K; Kose T
    Arch Esp Urol; 2022 Jun; 75(5):405-409. PubMed ID: 35983810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
    Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
    Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy.
    Downes MR; Xu B; van der Kwast TH
    Eur J Cancer; 2021 May; 148():432-439. PubMed ID: 33077335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern.
    van der Slot MA; Seyrek N; Kweldam CF; den Bakker MA; Busstra MB; Gan M; Klaver S; Rietbergen JBW; van Leenders GJLH
    World J Urol; 2022 Nov; 40(11):2723-2729. PubMed ID: 36190529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores.
    Okubo Y; Sato S; Hasegawa C; Koizumi M; Suzuki T; Yamamoto Y; Yoshioka E; Ono K; Washimi K; Yokose T; Kishida T; Miyagi Y
    Hum Pathol; 2023 May; 135():99-107. PubMed ID: 36738975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
    Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
    Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of corpora amylacea among prostate cancer cells: an unrecognised feature of intraductal carcinoma of the prostate.
    Sugie M; Takahara T; Ohashi A; Sassa N; Tsuzuki T
    Pathology; 2021 Aug; 53(5):574-578. PubMed ID: 34154844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
    Wissing M; Brimo F; Chevalier S; Scarlata E; McKercher G; O'Flaherty A; Aprikian S; Thibodeau V; Saad F; Carmel M; Lacombe L; Têtu B; Ekindi-Ndongo N; Latour M; Trudel D; Aprikian A
    BJU Int; 2019 Apr; 123(4):624-631. PubMed ID: 30113732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy.
    Karakoc S; Celik S; Kaya N; Bozkurt O; Ellidokuz H; Tuna B; Yorukoglu K; Mungan MU
    Int J Clin Pract; 2021 Jun; 75(6):e14099. PubMed ID: 33619822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
    Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
    Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.